Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Not a question, the fact is you believe the compounds are worth more then 10 million. To who? and why? Management has not advanced the science past Serviers current program. Plus other then proof of concept (with a stretch in SA)nothing else. Very promising if you have lab rats for potential recipients.
No revenue stream, yada,yada,yada!
How can you put a price tag on speculation. They have not advanced any of the compounds, and the current crew probably never will.
They are not even close. I could find proof of concept with silly putty and ADHD. They dropped the ball a long time ago.
Sad investment, hugh losses, sickening.
So more of the same. and .08 limbo next stop.
Even though it doesn't amount to any $, can anyone explain the recent bump in volume?
Thanks for the effort.
I think they should contact Seaside Therapeutics.
Patient? We are trading at .12!
There is a 4th scenario too. Nothing happens, we go down to zero, and it's over. I hope it doesn't happen to us, but it is not out of the question.
You always have an answer, and or comment that corrects imperfections in all of us.
Find me a barfbag!
Close. It starts at .08. It's the point of no return.
Or no announcement, and we go to stock limbo.
That's a good place to start. Ask if there is going to be an shareholders meeting.
Or in the case of cor, mouse shit, since mice are the only species to reap the benefits of Ampakines. To be honest, they must be doing a good job. I have not seen any mice with RD or SA for quite some time!
More high impact, more low impact, and yes the most frequently developed compound from cor more no impact!
What has changed to make you believe this? We are in hibernation. We don't hear from Jerry/Dylan, Neuro, Ombow. Why?
Maybe Varney is speechless, maybe he has nothing to say.
The truth is Ampakines have not been advanced, and with this crew may never be. I would be happy with .25 right now. Any takers?
shake it one more time. I was hoping for "yes definitely".
I bet he has a magic 8 ball. Ask it the following question for me.
"Will I become rich from investing in Cortex?"
Hope Varney is working hard to cut a deal or two.
In the end, the reality has set in. Nothing new to report from cor corporate, and the regular posters have left for the exits. Nothing left to criticize but each other.
The end for corx would be a sale of the company, or go out of business.
To rephrase your post, I hope a new beginning starts soon! Partner adhd sell rd/sa. Get a big infusion of cash too! The time is now!
check out curis (cris) today. Cancer cure on the brink of approval.
Stunning results. Wish cor had this much going.
We need to practice restraint when talking about corx.
This is not over by a long shot. Who knows how it will turn out. It's safe to assume we can touch bottom with one foot. Treading water up to our noses of course. They still have a chance. Irons in the embers (not fire).
Was it ever obvious? Until now, I don't think it was.
I still hold out hope with Dr. Varney being the new leader with something to prove. If he has any moxy at all he will cut a deal and turn this thing around. But, can he get ampakine technology to the big dance, and the big question Pharma co.'s are asking is at what cost.
Sometimes a good leader can see past the door handle. Is cor management looking through smoke colored glass. Do they really believe in their products?
Day late and 3 trillion short:0)
Apparently the street knows something about what was, or is about to be discussed with the FDA. Maybe I'll go and eat some crow...
The company has a unique delivery system. With it they will be able to simplify patient sedation, mostly in the form of pain relief. The applications for the technology are limitless. Certainly why Baker and Tang are so heavily invested.
The approval might take place quickly if they satisfy all of the FDA concerns. They have two more studies to run that they may or may not have started. They could already be finished. The point is, with good news it won't matter how long. Hope for the bridge loan or partnership. With that said I am very happy to own this stock!
Thanks, she ran the fragile X study for them in the midwest.
Haysaw, I got to see my oldest (25) play ball at the college level, team catcher. He went 3 for 4 with a triple, and two singles. Good luck. His brother is 18 months younger and is autistic. Why I was attracted to Cortex in the first place. His Neurologist thinks the management sucks too! She didn't use those exact works but...
Haysaw, got an extra ticket? I am a White Sox fan...
Healthcare Acquisition Activity on the Rise as Key Patents Run Out
The Bedford Report Provides Analyst Research on Amylin & Arena Pharmaceuticals
marketwire
NEW YORK, NY--(Marketwire - 03/24/11) - Merger and Acquisition activity in the healthcare sector has been on the upswing in recent quarters. Going forward larger healthcare firms are expected to continue searching for smaller, more speculative companies which are focusing on specific treatments and specialties in the medical sector. Recent reports suggest that not only is Big Pharma active in acquisitions, but also larger biotech firms are showing willingness to utilize their large resource pools to acquire smaller firms in a race to diversify and to build their reach. The Bedford Report examines the outlook for companies in the Healthcare Sector and provides research reports on Amylin Pharmaceuticals, Inc. (NASDAQ:AMLN - News) and Arena Pharmaceuticals, Inc. (NASDAQ:ARNA - News). Access to the full company reports can be found at:
www.bedfordreport.com/2011-03-AMLN
www.bedfordreport.com/2011-03-ARNA
A recent report from Deal Search Online claims that while the biotech sector saw a 40 percent drop in the number of M&A deals last year, the 115 deals in 2010 amounted to $57.5 billion, a 21 percent increase over 2009. The report suggests that the last decade saw an increase in the amount of biotech deals, led in part by pharmaceutical companies seeking new blockbuster drugs to fill the void left by drugs coming off patent.
The Bedford Report releases regular market updates on the Healthcare Sector so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at www.bedfordreport.com and get exclusive access to our numerous analyst reports and industry newsletters.
A safe and effective obesity drug could have astronomical earnings potential in North America. Obesity drugs have, however, proven to be one of the most difficult to gain approval. Yesterday Amylin Pharmaceuticals said they have suspended a mid-stage clinical trial of a combination obesity treatment to investigate a new "antibody-related laboratory finding" with one of the drugs.
The Bedford Report provides Analyst Research focused on equities that offer growth opportunities, value, and strong potential return. We strive to provide the most up-to-date market activities. We constantly create research reports and newsletters for our members. The Bedford Report has not been compensated by any of the above-mentioned publicly traded companies. The Bedford Report is compensated by other third party organizations for advertising services. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at http://www.bedfordreport.com/disclaimer
I hope so.
Ya but not a 100 shares at a time. Watch the volume today.
Not moving because of manipulation. Someone bought all day long.
My take is they liked the unlocked potential for sickle cell.
So much that they didn't want to walk away empty handed.
You speak loud and clear! That's why they are after the orphan indication. Unlike Stoll, Varney knows the fastest way to the big game is with little victories. Sickle cell is good! Partnering it will be better with a fast track to market approval. GFP this will not be a waste of money or time if they succeed, something they have not done yet. Plus ampakines need a winner even if it's a small one.
The answer is not in the indication, but rather how much money a potential partnership will bring. Personally I don't care if they go after compulsive farting if there is a partner willing to pony up.
Money will allow cor to move again. Selling the company for less then perceived value (Stoll/Varney's) is a pipe dream.
It's good to know that Varney is turning over every stone.
An orphan indication is a man on base. We finally have a real chance to score!